EP1801582A4 - Procede de presomption du metabolisme de medicament dans le foie humain et fonction hepatique - Google Patents

Procede de presomption du metabolisme de medicament dans le foie humain et fonction hepatique

Info

Publication number
EP1801582A4
EP1801582A4 EP05780351A EP05780351A EP1801582A4 EP 1801582 A4 EP1801582 A4 EP 1801582A4 EP 05780351 A EP05780351 A EP 05780351A EP 05780351 A EP05780351 A EP 05780351A EP 1801582 A4 EP1801582 A4 EP 1801582A4
Authority
EP
European Patent Office
Prior art keywords
chimeric animal
liver
human
human liver
presomption
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
EP05780351A
Other languages
German (de)
English (en)
Other versions
EP1801582B1 (fr
EP1801582A1 (fr
Inventor
Shin-Ichi Ninomiya
Yoshihiro Ohzone
Yasuhisa Adachi
Toru Horie
Yoshinori Soeno
Tae Inoue
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Phoenixbio Co Ltd
Sekisui Medical Co Ltd
Original Assignee
Daiichi Pure Chemicals Co Ltd
Phoenixbio Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Pure Chemicals Co Ltd, Phoenixbio Co Ltd filed Critical Daiichi Pure Chemicals Co Ltd
Publication of EP1801582A1 publication Critical patent/EP1801582A1/fr
Publication of EP1801582A4 publication Critical patent/EP1801582A4/fr
Application granted granted Critical
Publication of EP1801582B1 publication Critical patent/EP1801582B1/fr
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • G01N33/5038—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects involving detection of metabolites per se
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/15—Medicinal preparations ; Physical properties thereof, e.g. dissolubility
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biotechnology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measurement Of The Respiration, Hearing Ability, Form, And Blood Characteristics Of Living Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
EP05780351A 2004-08-20 2005-08-19 Procede de presomption du metabolisme de medicament dans le foie humain et fonction hepatique Expired - Lifetime EP1801582B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2004240827 2004-08-20
PCT/JP2005/015148 WO2006019162A1 (fr) 2004-08-20 2005-08-19 Procédé de présomption du métabolisme de médicament dans le foie humain et fonction hépatique

Publications (3)

Publication Number Publication Date
EP1801582A1 EP1801582A1 (fr) 2007-06-27
EP1801582A4 true EP1801582A4 (fr) 2007-12-19
EP1801582B1 EP1801582B1 (fr) 2010-03-17

Family

ID=35907545

Family Applications (1)

Application Number Title Priority Date Filing Date
EP05780351A Expired - Lifetime EP1801582B1 (fr) 2004-08-20 2005-08-19 Procede de presomption du metabolisme de medicament dans le foie humain et fonction hepatique

Country Status (9)

Country Link
US (1) US20080199847A1 (fr)
EP (1) EP1801582B1 (fr)
JP (1) JP4854509B2 (fr)
KR (1) KR101159573B1 (fr)
CN (1) CN101014855A (fr)
AT (1) ATE461448T1 (fr)
CA (1) CA2577644C (fr)
DE (1) DE602005020042D1 (fr)
WO (1) WO2006019162A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2587886A1 (fr) * 2004-11-16 2006-05-26 Hiroshima Industrial Promotion Organization Procede de criblage des candidats destines a un medicament
JP2011106846A (ja) * 2009-11-13 2011-06-02 Hamamatsu Univ School Of Medicine 新規ｎｓａｉｄ潰瘍リスク判定方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032009A1 (fr) * 1999-11-02 2001-05-10 The University Of Connecticut Propagation d'hepatocytes chez des animaux
WO2001067854A1 (fr) * 2000-03-17 2001-09-20 Kneteman Norman M Modele d'animal chimerique sensible a l'infection par le virus de l'hepatite c humaine
WO2003000848A2 (fr) * 2001-06-22 2003-01-03 Stemcells, Inc. Cellules de greffe hepatique, dosages, et leurs utilisations
EP1552740A1 (fr) * 2004-01-09 2005-07-13 Institut Pasteur Modèle murin comprenant hepatocytes humains - utilisation pour criblage de composés

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL106368A0 (en) * 1992-07-24 1993-11-15 Univ Pennsylvania Non-native liver generation in an animal with impaired native liver function,by cell implantation
US6129911A (en) * 1998-07-10 2000-10-10 Rhode Island Hospital, A Lifespan Partner Liver stem cell
AU779706B2 (en) * 1999-01-19 2005-02-10 University Of North Carolina At Chapel Hill, The Human liver progenitors
JP2002045087A (ja) * 2000-05-19 2002-02-12 Japan Science & Technology Corp キメラ動物
JP4907843B2 (ja) * 2002-03-25 2012-04-04 公益財団法人ひろしま産業振興機構 ヒト肝細胞増殖方法とヒト肝細胞の取得方法

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001032009A1 (fr) * 1999-11-02 2001-05-10 The University Of Connecticut Propagation d'hepatocytes chez des animaux
WO2001067854A1 (fr) * 2000-03-17 2001-09-20 Kneteman Norman M Modele d'animal chimerique sensible a l'infection par le virus de l'hepatite c humaine
WO2003000848A2 (fr) * 2001-06-22 2003-01-03 Stemcells, Inc. Cellules de greffe hepatique, dosages, et leurs utilisations
EP1552740A1 (fr) * 2004-01-09 2005-07-13 Institut Pasteur Modèle murin comprenant hepatocytes humains - utilisation pour criblage de composés

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
TATENO C ET AL: "Near completely humanized liver in mice shows human-type metabolic responses to drugs", AMERICAN JOURNAL OF PATHOLOGY, PHILADELPHIA, PA, US, vol. 165, no. 3, September 2004 (2004-09-01), pages 901 - 912, XP002996759, ISSN: 0002-9440 *

Also Published As

Publication number Publication date
WO2006019162A1 (fr) 2006-02-23
JP4854509B2 (ja) 2012-01-18
JPWO2006019162A1 (ja) 2008-05-08
KR20070051277A (ko) 2007-05-17
KR101159573B1 (ko) 2012-06-26
DE602005020042D1 (de) 2010-04-29
ATE461448T1 (de) 2010-04-15
CN101014855A (zh) 2007-08-08
US20080199847A1 (en) 2008-08-21
EP1801582B1 (fr) 2010-03-17
CA2577644C (fr) 2012-11-27
EP1801582A1 (fr) 2007-06-27
CA2577644A1 (fr) 2006-02-23

Similar Documents

Publication Publication Date Title
Cassar et al. Use of zebrafish in drug discovery toxicology
Schmitz et al. Megalin deficiency offers protection from renal aminoglycoside accumulation
Sayaf et al. The nuclear receptor PXR in chronic liver disease
Bourdi et al. Role of IL-6 in an IL-10 and IL-4 double knockout mouse model uniquely susceptible to acetaminophen-induced liver injury
Wang et al. Endogenous dynorphin protects against neurotoxin-elicited nigrostriatal dopaminergic neuron damage and motor deficits in mice
Vlantis et al. TLR-independent anti-inflammatory function of intestinal epithelial TRAF6 signalling prevents DSS-induced colitis in mice
Su et al. Sorafenib and its derivative SC-1 exhibit antifibrotic effects through signal transducer and activator of transcription 3 inhibition
Kirla et al. From the cover: zebrafish larvae are insensitive to stimulation by cocaine: importance of exposure route and toxicokinetics
Endig et al. Dual role of the adaptive immune system in liver injury and hepatocellular carcinoma development
Woodhead et al. Analyzing the Mechanisms Behind Macrolide Antibiotic-Induced Liver Injury Using Quantitative Systems Toxicology Modeling: Woodhead et al.
Bahari-Javan et al. HDAC1 regulates fear extinction in mice
Hu et al. LXRα-mediated downregulation of FOXM1 suppresses the proliferation of hepatocellular carcinoma cells
Huang et al. Liver X receptor inverse agonist SR9243 suppresses nonalcoholic steatohepatitis intrahepatic inflammation and fibrosis
Doodnaught et al. Pharmacokinetic and pharmacodynamic modelling after subcutaneous, intravenous and buccal administration of a high-concentration formulation of buprenorphine in conscious cats
Mantry et al. High Sustained Virologic Response Rates in Liver Transplant Recipients With Recurrent HCV Genotype 1 Infection Receiving ABT-450/r/Ombitasvir+ Dasabuvir Plus Ribavirin: 198
Wu et al. A novel Huntington’s disease assessment platform to support future drug discovery and development
Kwon et al. In vitro and in vivo study on the toxic effects of propiconazole fungicide in the pathogenesis of liver fibrosis
Henry et al. Prepulse inhibition in HIV-1 gp120 transgenic mice after withdrawal from chronic methamphetamine
Toledo-Rodriguez et al. Stress during puberty boosts metabolic activation associated with fear-extinction learning in hippocampus, basal amygdala and cingulate cortex
Ohgami et al. Hearing impairments caused by genetic and environmental factors
Morawska et al. The effects of muscimol and AMN082 injections into the medial prefrontal cortex on the expression and extinction of conditioned fear in mice
Lengersdorf et al. Blocking NMDA-receptors in the pigeon’s “prefrontal” caudal nidopallium impairs appetitive extinction learning in a sign-tracking paradigm
Edvardsson et al. An inhibitory GLP-1 circuit in the lateral septum modulates reward processing and alcohol intake in rodents
Albernaz-Mariano et al. The infralimbic mineralocorticoid blockage prevents the stress-induced impairment of aversive memory extinction in rats
EP1801582A4 (fr) Procede de presomption du metabolisme de medicament dans le foie humain et fonction hepatique

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20070219

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
A4 Supplementary search report drawn up and despatched

Effective date: 20071119

RIC1 Information provided on ipc code assigned before grant

Ipc: G01N 33/50 20060101AFI20071113BHEP

17Q First examination report despatched

Effective date: 20080218

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: SEKISUI MEDICAL CO., LTD.

Owner name: PHOENIXBIO CO., LTD.

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

RTI1 Title (correction)

Free format text: METHOD OF PREDICTING THE METABOLISM OF DRUG IN HUMAN LIVER AND LIVER FUNCTION

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 602005020042

Country of ref document: DE

Date of ref document: 20100429

Kind code of ref document: P

REG Reference to a national code

Ref country code: NL

Ref legal event code: VDEP

Effective date: 20100317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20100317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: FI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: LV

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: SI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: CY

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: EE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100628

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100618

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: RO

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IS

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100717

Ref country code: BG

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100617

Ref country code: CZ

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

Ref country code: SK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

REG Reference to a national code

Ref country code: HU

Ref legal event code: AG4A

Ref document number: E008533

Country of ref document: HU

PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100719

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

26N No opposition filed

Effective date: 20101220

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: CH

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

Ref country code: LI

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20100819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: TR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20100317

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 12

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 13

REG Reference to a national code

Ref country code: FR

Ref legal event code: PLFP

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20180823

Year of fee payment: 14

Ref country code: DE

Payment date: 20180807

Year of fee payment: 14

Ref country code: FR

Payment date: 20180712

Year of fee payment: 14

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20180815

Year of fee payment: 14

Ref country code: HU

Payment date: 20180724

Year of fee payment: 14

REG Reference to a national code

Ref country code: DE

Ref legal event code: R119

Ref document number: 602005020042

Country of ref document: DE

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20190819

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: HU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190820

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20200303

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190831

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190819

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20190819